Screener
BioCryst Pharmaceuticals BCRX Business Segments — Acquired in-process research and development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:ResearchAndDevelopmentExpenseAcquiredInProcessCost.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues | $218,250 | $163,353 | $374,663 | $308,887 |
| Less1: | ||||
| Cost of product sales | 3,840 | 2,798 | 9,217 | 7,366 |
| Acquired in-process research and development | — | — | 697,761 | — |
| Research and development (excluding stock-based compensation) | ||||
| Navenibart | 17,328 | — | 27,069 | — |
| BCX17725 | 5,240 | 3,316 | 7,147 | 5,772 |
| Berotralstat | 1,611 | 4,766 | 3,407 | 6,640 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's business segments — acquired in-process research and development?
- BioCryst Pharmaceuticals (BCRX) reported business segments — acquired in-process research and development of $0 in Q2 2026.
- What does business segments — acquired in-process research and development mean?
- Captures the value of research and development projects acquired through business combinations that have not yet reached technological feasibility. This reflects the company's strategy for inorganic growth and long-term pipeline expansion.
Ask your AI about BioCryst Pharmaceuticals's business segments — acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude